Prevalence of pulmonary arteriovenous malformations (PAVMs) and occurrenceof neurological symptoms in patients with hereditary haemorrhagic telangiectasia (HHT)
Ad. Kjeldsen et al., Prevalence of pulmonary arteriovenous malformations (PAVMs) and occurrenceof neurological symptoms in patients with hereditary haemorrhagic telangiectasia (HHT), J INTERN M, 248(3), 2000, pp. 255-262
Citations number
27
Categorie Soggetti
General & Internal Medicine","Medical Research General Topics
Background, Hereditary haemorrhagic telangiectasia (HHT) is a dominantly in
herited disease. HHT is characterized by a wide variety of clinical manifes
tations, including pulmonary arteriovenous malformations (PAVMs) and neurol
ogical symptoms,
Objective. To estimate ii) the prevalence of PAVM, and (ii) the occurrence
of neurological symptoms in a geographical well-defined population of HHT p
atients,
Methods. HHT family members were invited to a clinical examination includin
g registration of HHT manifestations, screening for pulmonary arteriovenous
malformations and neurological evaluation. Two groups served as controls:
(i) first-degree relatives without any signs of HHT: and (ii) age- and gend
er-matched controls.
Setting, Odense University Hospital.
Subjects, HHT patients identified in a cross-sectional family survey carrie
d out in the County of Fyn, Denmark.
Results. Included in the study were 169 HHT family members representing 24
families. They included both HHT patients and their first-degree relatives.
The criteria of HHT were fulfilled in 75 participants; of these, 59 had a
screening procedure performed, and PAVMs were demonstrated at pulmonary ang
iography (PA) in 18. Seven of the HHT patients had a history of cerebral st
roke, compared with none of their healthy first-degree relatives,
Conclusion. The prevalence of PAVM was 24% amongst HHT patients. The study
confirmed an increased prevalence of neurological symptoms amongst HHT pati
ents; the odds ratio was estimated to be 7.6. In order to enable prevention
of these complications, screening for PAVM should become an integral part
of the medical care for HHT patients.